139 related articles for article (PubMed ID: 18710384)
21. Refractory epidermolysis bullosa acquisita: successful treatment with rituximab.
Saha M; Cutler T; Bhogal B; Black MM; Groves RW
Clin Exp Dermatol; 2009 Dec; 34(8):e979-80. PubMed ID: 20055876
[No Abstract] [Full Text] [Related]
22. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.
Dalakas MC; Rakocevic G; Salajegheh M; Dambrosia JM; Hahn AF; Raju R; McElroy B
Ann Neurol; 2009 Mar; 65(3):286-93. PubMed ID: 19334068
[TBL] [Abstract][Full Text] [Related]
23. Chimeric monoclonal anti-CD20 antibody (rituximab)--an effective treatment for a patient with relapsing hairy cell leukaemia.
Hagberg H
Med Oncol; 1999 Sep; 16(3):221-2. PubMed ID: 10523804
[TBL] [Abstract][Full Text] [Related]
24. Hairy cell leukemia: treatment successes in the past 25 years.
Golomb HM
J Clin Oncol; 2008 Jun; 26(16):2607-9. PubMed ID: 18509168
[No Abstract] [Full Text] [Related]
25. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab.
von Bonin M; Oelschlägel U; Radke J; Stewart M; Ehninger G; Bornhauser M; Platzbecker U
Transplantation; 2008 Sep; 86(6):875-9. PubMed ID: 18813113
[TBL] [Abstract][Full Text] [Related]
26. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
[TBL] [Abstract][Full Text] [Related]
27. Comparative analysis of immunophenotypic methods for the assessment of minimal residual disease in hairy cell leukemia.
Bengiò R; Narbaitz MI; Sarmiento MA; Palacios MF; Scolnik MP
Haematologica; 2000 Nov; 85(11):1227-9. PubMed ID: 11064481
[No Abstract] [Full Text] [Related]
28. Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab.
Pfütze M; Eming R; Kneisel A; Kuhlmann U; Hoyer J; Hertl M
Dermatology; 2009; 218(3):237-45. PubMed ID: 19088461
[TBL] [Abstract][Full Text] [Related]
29. Rituximab for myasthenia gravis: three case reports and review of the literature.
Stieglbauer K; Topakian R; Schäffer V; Aichner FT
J Neurol Sci; 2009 May; 280(1-2):120-2. PubMed ID: 19272616
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases.
Bussone G; Ribeiro E; Dechartres A; Viallard JF; Bonnotte B; Fain O; Godeau B; Michel M
Am J Hematol; 2009 Mar; 84(3):153-7. PubMed ID: 19123460
[TBL] [Abstract][Full Text] [Related]
31. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab.
Pellkofer HL; Suessmair C; Schulze A; Hohlfeld R; Kuempfel T
Mult Scler; 2009 Aug; 15(8):1006-8. PubMed ID: 19667025
[TBL] [Abstract][Full Text] [Related]
32. Recurrence of Wegener's granulomatosis with de novo intraoral presentation treated successfully with rituximab.
Staines KS; Higgins B
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Jul; 108(1):76-80. PubMed ID: 19451001
[TBL] [Abstract][Full Text] [Related]
33. Rituximab to treat active SLE in a hemodialysis patient.
Nadri QJ
Saudi J Kidney Dis Transpl; 2009 Nov; 20(6):1085-6. PubMed ID: 19861879
[No Abstract] [Full Text] [Related]
34. Giant cell hepatitis and autoimmune hemolytic anemia successfully treated with rituximab.
Miloh T; Manwani D; Morotti R; Sukru E; Shneider B; Kerkar N
J Pediatr Gastroenterol Nutr; 2007 May; 44(5):634-6. PubMed ID: 17460499
[No Abstract] [Full Text] [Related]
35. Long-term follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukemia.
Benz R; Siciliano RD; Stussi G; Fehr J
Eur J Haematol; 2009 Mar; 82(3):194-200. PubMed ID: 19077050
[TBL] [Abstract][Full Text] [Related]
36. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production.
Pepper RJ; Fabre MA; Pavesio C; Gaskin G; Jones RB; Jayne D; Pusey CD; Salama AD
Rheumatology (Oxford); 2008 Jul; 47(7):1104-5. PubMed ID: 18492710
[No Abstract] [Full Text] [Related]
37. [Efficacy of rituximab in hairy cell leukemia].
Malfuson JV; Doghmi K; Fagot T; Souleau B; De Revel T; Nedellec G
Presse Med; 2006 May; 35(5 Pt 1):801-2. PubMed ID: 16710151
[TBL] [Abstract][Full Text] [Related]
38. Rituximab as an effective treatment of hyperhemolysis syndrome in sickle cell anemia.
Bachmeyer C; Maury J; Parrot A; Bachir D; Stankovic K; Girot R; Lionnet F
Am J Hematol; 2010 Jan; 85(1):91-2. PubMed ID: 20029943
[No Abstract] [Full Text] [Related]
39. Is rituximab effective in acquired von Willebrand syndrome?
Mazoyer E; Fain O; Dhote R; Laurian Y
Br J Haematol; 2009 Mar; 144(6):967-8. PubMed ID: 19120364
[No Abstract] [Full Text] [Related]
40. Rituximab in thrombotic microangiopathy.
Castagna L; Todisco E; Sarina B; Santoro A
Br J Haematol; 2007 Oct; 139(1):166; author reply 166-7. PubMed ID: 17854324
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
